Inês Martins, PhD, managing science editor —

Preventive treatment with Takhzyro (lanadelumab) significantly reduces the number of swelling attacks in people with hereditary angioedema (HAE), even in the early phases of treatment, a post hoc analysis from the HELP trial shows. The benefits are evident within two weeks of treatment and progressively increase over time, the researchers…

Preventive treatment with Takhzyro (lanadelumab) is effective at delaying and lowering the monthly rate of attacks in a broad range of patients with hereditary angioedema (HAE), a study has found. The therapy did so by inducing sustained increases in blood concentrations of the treatment. The response was not…

After showing a sustained reduction in kallikrein levels in animal models, Intellia Therapeutics will be moving forward with the development of its gene-editing candidate NTLA-2002 for the treatment of hereditary angioedema (HAE). The company is now planning to ask regulatory authorities to advance the candidate into clinical studies…

A small molecule inhibitor being developed for hereditary angioedema (HAE) treatment, called PHA121, was as effective as Firazyr (icatibant acetate) — an approved therapy with a similar mechanism of action — at reversing bradykinin-induced changes in blood pressure in monkeys, results of a preclinical study show.

The European Medicines Agency has validated BioCryst Pharmaceuticals‘ application requesting the approval of berotralstat as a once-daily oral treatment to prevent swelling attacks in people with hereditary angioedema (HAE). The Committee for Medicinal Products for Human Use, an advisory committee for the European Union’s regulatory agency,…

The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency, has recommended Ruconest (conestat alfa) for approval as treatment for acute swelling episodes in children with hereditary angioedema (HAE). In the European Union, Pharming‘s Ruconest is approved for…

Patients who experience an angioedema attack during treatment with angiotensin-converting enzyme inhibitors — a kind of medication for high blood pressure and heart failure — may safely switch to a different kind of blood pressure medication called angiotensin II receptor blockers, a study found. The study, “Angiotensin II receptor blockers…

Takhzyro (lanadelumab), a kallikrein inhibitor by Shire, has been approved in Europe for the routine prevention of hereditary angioedema (HAE) attacks in patients ages 12 and older, making it the first antibody available in the EU for this indication. The European Commission’s decision comes shortly after the Committee for Medicinal Products…

Routine treatment with Shire‘s Takhzyro (lanadelumab) — given as a 300 mg dose every two weeks — significantly reduces the rate of acute attacks in hereditary angioedema (HAE) patients age 12 and older, a Phase 3 trial shows. The treatment also kept more patients attack-free during the 26-week study, reduced…

The U.S. Food and Drug Administration recently approved Shire’s Cinryze (C1 esterase inhibitor [human]) to help prevent angioedema attacks in children 6 and older who live with hereditary angioedema (HAE). Cinryze was first approved in the U.S. in 2008 for routine preventive treatment against attacks in…